Triple-Negative Breast Cancer (TNBC) Recruiting Phase 3 Trials for Doxorubicin (DB00997)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03197935A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast CancerTreatment